Treace Medical Concepts (TMCI) to Release Quarterly Earnings on Thursday

Treace Medical Concepts (NASDAQ:TMCI) is anticipated to issue its Q4 2025 results after the market closes on Thursday, February 26th. Analysts expect Treace Medical Concepts to post earnings of ($0.15) per share and revenue of $61.7630 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Friday, February 27, 2026 at 8:00 AM ET.

Treace Medical Concepts Trading Up 1.1%

Shares of Treace Medical Concepts stock opened at $1.85 on Thursday. The company has a market cap of $117.88 million, a price-to-earnings ratio of -2.31 and a beta of 0.74. Treace Medical Concepts has a 1 year low of $1.81 and a 1 year high of $10.30. The company’s fifty day simple moving average is $2.45 and its 200-day simple moving average is $4.60. The company has a current ratio of 3.37, a quick ratio of 2.36 and a debt-to-equity ratio of 0.60.

Institutional Investors Weigh In On Treace Medical Concepts

Large investors have recently made changes to their positions in the company. Armistice Capital LLC increased its position in shares of Treace Medical Concepts by 0.9% during the 3rd quarter. Armistice Capital LLC now owns 6,316,000 shares of the company’s stock worth $42,380,000 after purchasing an additional 56,000 shares in the last quarter. Millennium Management LLC grew its stake in Treace Medical Concepts by 12.7% during the third quarter. Millennium Management LLC now owns 1,710,140 shares of the company’s stock worth $11,475,000 after buying an additional 192,929 shares during the last quarter. Parkman Healthcare Partners LLC raised its stake in shares of Treace Medical Concepts by 0.4% in the third quarter. Parkman Healthcare Partners LLC now owns 847,675 shares of the company’s stock valued at $5,688,000 after acquiring an additional 3,677 shares during the last quarter. Kotler Kevin acquired a new position in shares of Treace Medical Concepts in the 4th quarter worth approximately $1,162,000. Finally, Dimensional Fund Advisors LP grew its position in Treace Medical Concepts by 11.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 273,376 shares of the company’s stock worth $670,000 after acquiring an additional 28,912 shares during the last quarter. Institutional investors own 84.08% of the company’s stock.

Wall Street Analysts Forecast Growth

TMCI has been the topic of several research reports. Stifel Nicolaus dropped their price objective on shares of Treace Medical Concepts from $5.00 to $3.00 and set a “hold” rating on the stock in a report on Wednesday, January 7th. JPMorgan Chase & Co. reaffirmed an “underweight” rating and issued a $5.00 price target (down previously from $8.00) on shares of Treace Medical Concepts in a report on Friday, November 7th. Weiss Ratings restated a “sell (e+)” rating on shares of Treace Medical Concepts in a research report on Wednesday, January 21st. UBS Group decreased their price target on shares of Treace Medical Concepts from $6.50 to $5.85 and set a “neutral” rating on the stock in a research note on Friday, November 7th. Finally, Wall Street Zen lowered shares of Treace Medical Concepts from a “hold” rating to a “sell” rating in a report on Sunday. Four research analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Treace Medical Concepts currently has an average rating of “Reduce” and a consensus price target of $4.21.

Treace Medical Concepts Company Profile

Treace Medical Concepts, Inc is a medical technology company specializing in the development and commercialization of innovative surgical solutions for foot and ankle conditions. The company’s flagship product, the Lapiplasty 3D Bunion Correction System, addresses the underlying joint instability that causes bunion deformity through a patented, multi-plane correction approach. The system combines proprietary instrumentation, fixation plates, and a comprehensive surgical protocol designed to improve patient outcomes and reduce recurrence rates.

The Lapiplasty System has received clearance from the U.S.